{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:14:26Z","timestamp":1780586066537,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"AbbVie GK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01772-4","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T03:26:25Z","timestamp":1778383585000},"page":"3167-3188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct04750213","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-2573","authenticated-orcid":false,"given":"Toshiyuki","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Tanizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5495-4956","authenticated-orcid":false,"given":"Kenshi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2668-4853","authenticated-orcid":false,"given":"Naoko","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5176-8493","authenticated-orcid":false,"given":"Eri","family":"Iwashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3055-5202","authenticated-orcid":false,"given":"Keiichi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"issue":"1","key":"1772_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14876","volume":"33","author":"SN Sanchez-Melendez","year":"2024","unstructured":"Sanchez-Melendez SN, Malik R, Patel PM, Milosavljevic S, Patel S, Nambudiri VE. Pyoderma gangrenosum and impact on quality of life: a narrative review. Exp Dermatol. 2024;33(1):e14876.","journal-title":"Exp Dermatol"},{"issue":"4","key":"1772_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042440","volume":"25","author":"M \u0141yko","year":"2024","unstructured":"\u0141yko M, Rygu\u0142a A, Kowalski M, Karska J, Jankowska-Konsur A. The pathophysiology and treatment of pyoderma gangrenosum-current options and new perspectives. Int J Mol Sci. 2024;25(4):2440.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1772_CR3","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.1111\/1346-8138.16845","volume":"50","author":"T Yamamoto","year":"2023","unstructured":"Yamamoto T, Yamasaki K, Yamanaka K, et\u00a0al. Clinical guidance of pyoderma gangrenosum 2022. J Dermatol. 2023;50(9):e253\u201375.","journal-title":"J Dermatol"},{"issue":"2","key":"1772_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jamadermatol.2022.5437","volume":"159","author":"S Lee","year":"2023","unstructured":"Lee S, Lee JY, Ju HJ, et\u00a0al. Association of all-cause and cause-specific mortality risks with pyoderma gangrenosum. JAMA Dermatol. 2023;159(2):151\u20139.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1772_CR5","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1038\/jid.2012.130","volume":"132","author":"SM Langan","year":"2012","unstructured":"Langan SM, Groves RW, Card TR, Gulliford MC. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Investig Dermatol. 2012;132(9):2166\u201370.","journal-title":"J Investig Dermatol"},{"issue":"2","key":"1772_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jaad.2019.08.001","volume":"83","author":"A Xu","year":"2020","unstructured":"Xu A, Balgobind A, Strunk A, Garg A, Alloo A. Prevalence estimates for pyoderma gangrenosum in the United States: an age- and sex-adjusted population analysis. J Am Acad Dermatol. 2020;83(2):425\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1772_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/exd.70112","volume":"34","author":"L Norouzi-Barough","year":"2025","unstructured":"Norouzi-Barough L, Biglari S, Sherkat R, Gudjonsson JE, Hakonarson H, Vahidnezhad H. A systematic review of Mendelian pyoderma gangrenosum: clinical and genetic characteristics in 120 published patients. Exp Dermatol. 2025;34(5):e70112.","journal-title":"Exp Dermatol"},{"issue":"1","key":"1772_CR8","volume":"16","author":"AN Park","year":"2024","unstructured":"Park AN, Raj A, Bajda J, Gorantla VR. Narrative review: pyoderma gangrenosum. Cureus. 2024;16(1):e51805.","journal-title":"Cureus"},{"key":"1772_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2958","volume":"350","author":"AD Ormerod","year":"2015","unstructured":"Ormerod AD, Thomas KS, Craig FE, et\u00a0al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. Br Med J. 2015;350:h2958.","journal-title":"Br Med J"},{"issue":"4","key":"1772_CR10","volume":"16","author":"R Rukhshan","year":"2024","unstructured":"Rukhshan R, Eliogu C, Mistry A, Brar S, Mohd AA, Ruck L. Pyoderma gangrenosum: a case highlighting the importance of timely diagnosis. Cureus. 2024;16(4):e57762.","journal-title":"Cureus"},{"issue":"8","key":"1772_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.70733","volume":"22","author":"M Kaur","year":"2025","unstructured":"Kaur M, Diaz MJ, Anthony M, et\u00a0al. Treatments for pyoderma gangrenosum: a systematic review and single-arm meta-analysis of systemic therapies. Int Wound J. 2025;22(8):e70733.","journal-title":"Int Wound J"},{"issue":"11","key":"1772_CR12","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/1346-8138.13937","volume":"44","author":"S Inoue","year":"2017","unstructured":"Inoue S, Furuta JI, Fujisawa Y, et\u00a0al. Pyoderma gangrenosum and underlying diseases in Japanese patients: a regional long-term study. J Dermatol. 2017;44(11):1281\u20134.","journal-title":"J Dermatol"},{"issue":"9","key":"1772_CR13","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/j.1468-3083.2009.03199.x","volume":"23","author":"E Ruocco","year":"2009","unstructured":"Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol. 2009;23(9):1008\u201317.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4 Suppl 1","key":"1772_CR14","first-page":"S774","volume":"35","author":"SW Muhammad","year":"2023","unstructured":"Muhammad SW, Hassan N, Khan S, Gohar A. Current and emerging trends in the management of pyoderma gangrenosum: a literature review. J Ayub Med Coll Abbottabad. 2023;35(4 Suppl 1):S774\u201384.","journal-title":"J Ayub Med Coll Abbottabad"},{"issue":"4","key":"1772_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/gut.2005.074815","volume":"55","author":"TN Brooklyn","year":"2006","unstructured":"Brooklyn TN, Dunnill MG, Shetty A, et\u00a0al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505\u20139.","journal-title":"Gut"},{"issue":"14","key":"1772_CR16","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-023-01931-3","volume":"83","author":"J Dissemond","year":"2023","unstructured":"Dissemond J, Marzano AV, Hampton PJ, Ortega-Loayza AG. Pyoderma gangrenosum: treatment options. Drugs. 2023;83(14):1255\u201367.","journal-title":"Drugs"},{"issue":"6","key":"1772_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22062922","volume":"22","author":"K Romanowska-Pr\u00f3chnicka","year":"2021","unstructured":"Romanowska-Pr\u00f3chnicka K, Felis-Giemza A, Olesi\u0144ska M, Wojdasiewicz P, Paradowska-Gorycka A, Szukiewicz D. The role of TNF-\u03b1 and anti-TNF-\u03b1 agents during preconception, pregnancy, and breastfeeding. Int J Mol Sci. 2021;22(6):2922.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1772_CR18","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/1346-8138.15533","volume":"47","author":"K Yamasaki","year":"2020","unstructured":"Yamasaki K, Yamanaka K, Zhao Y, et\u00a0al. Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: twenty-six-week phase 3 open-label study. J Dermatol. 2020;47(12):1383\u201390.","journal-title":"J Dermatol"},{"issue":"5","key":"1772_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/1346-8138.16337","volume":"49","author":"K Yamasaki","year":"2022","unstructured":"Yamasaki K, Yamanaka K, Zhao Y, et\u00a0al. Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: final analysis of a 52-week phase 3 open-label study. J Dermatol. 2022;49(5):479\u201387.","journal-title":"J Dermatol"},{"issue":"2","key":"1772_CR20","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/1346-8138.17547","volume":"52","author":"T Yamamoto","year":"2025","unstructured":"Yamamoto T, Yamanaka K, Yamasaki K, et\u00a0al. Real-world safety and effectiveness of adalimumab in patients with pyoderma gangrenosum: interim analysis of a postmarketing observational study in Japan. J Dermatol. 2025;52(2):270\u201380.","journal-title":"J Dermatol"},{"key":"1772_CR21","unstructured":"AbbVie GK. Humira syringe\/pen [package insert]. [Sep 2025]; https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00068024.pdf. Accessed 24 Feb 2026."},{"issue":"6","key":"1772_CR22","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.jaad.2016.07.049","volume":"75","author":"SR Wilkes","year":"2016","unstructured":"Wilkes SR, Williams HC, Ormerod AD, et\u00a0al. Is speed of healing a good predictor of eventual healing of pyoderma gangrenosum? J Am Acad Dermatol. 2016;75(6):1216\u201320.e2.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1772_CR23","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0304-3959(75)90075-5","volume":"1","author":"EE Ohnhaus","year":"1975","unstructured":"Ohnhaus EE, Adler R. Methodological problems in the measurement of pain: a comparison between the verbal rating scale and the visual analogue scale. Pain. 1975;1(4):379\u201384.","journal-title":"Pain"},{"issue":"4","key":"1772_CR24","first-page":"560","volume":"31","author":"S Hamaguchi","year":"2011","unstructured":"Hamaguchi S. The assessment of pain. J Jpn Soc Clin Anesth. 2011;31(4):560\u20139.","journal-title":"J Jpn Soc Clin Anesth"},{"issue":"4","key":"1772_CR25","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3776","volume":"101","author":"L Sch\u00f8sler","year":"2021","unstructured":"Sch\u00f8sler L, Fogh K, Bech R. Pyoderma gangrenosum: a retrospective study of clinical characteristics, comorbidities, response to treatment and mortality related to prednisone dose. Acta Derm Venereol. 2021;101(4):adv00431.","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"1772_CR26","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/ecco-jcc\/jjw060","volume":"10","author":"H Ogata","year":"2016","unstructured":"Ogata H, Watanabe M, Matsui T, et\u00a0al. Safety of adalimumab and predictors of adverse events in 1693 Japanese patients with Crohn\u2019s disease. J Crohns Colitis. 2016;10(9):1033\u201341.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"1772_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.5217\/ir.2020.00033","volume":"19","author":"H Ogata","year":"2021","unstructured":"Ogata H, Hagiwara T, Kawaberi T, et\u00a0al. Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study. Intest Res. 2021;19(4):419\u201329.","journal-title":"Intest Res"},{"issue":"1","key":"1772_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejr.2025.11.001","volume":"48","author":"DB G\u00f6kten","year":"2026","unstructured":"G\u00f6kten DB, Mercan R. Pyoderma gangrenosum in a patient with rheumatoid arthritis treated with adalimumab: a case-based review. Egypt Rheumatol. 2026;48(1):67\u201370.","journal-title":"Egypt Rheumatol"},{"key":"1772_CR29","first-page":"449","volume":"15","author":"VF Martinelli","year":"2022","unstructured":"Martinelli VF, Martinelli Barbosa P, Dantas de Oliveira LS, de Melo LALV, Casa Nova JM, de Brito CAA. Atypical forms of pyoderma gangrenosum in inflammatory bowel disease: report of four cases and literature review. Int Med Case Rep J. 2022;15:449\u201356.","journal-title":"Int Med Case Rep J"},{"issue":"4","key":"1772_CR30","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jaad.2009.05.030","volume":"62","author":"J Miller","year":"2010","unstructured":"Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol. 2010;62(4):646\u201354.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1772_CR31","first-page":"721","volume":"23","author":"M Werner","year":"2025","unstructured":"Werner M, Stromer W, H\u00fcning S, et\u00a0al. Supportive pain therapy in dermatology. J Dtsch Dermatol Ges. 2025;23(6):721\u201345.","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01772-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01772-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01772-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:53:28Z","timestamp":1780584808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01772-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,10]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1772"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01772-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,10]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Toshiyuki Yamamoto received speaker or consulting fees from AbbVie. Hideaki Tanizaki received honoraria from AbbVie, Sanofi, Eli Lilly, Maruho, Sun Pharmaceutical Industries Limited, Mitsubishi Tanabe, Janssen, Torii, and Kyowa Kirin; contract research and collaborative research funding from Sun Pharmaceutical Industries Limited, Eisai, Maruho, and AbbVie; and scholarship donations from Sun Pharmaceutical Industries Limited, Eisai, Maruho, Taiho Pharmaceutical, Torii, Kyowa Kirin, Mitsubishi Tanabe, UCB, and Eli Lilly. Kenshi Yamasaki received research grants from AbbVie during the conduct of the study; research grants from Kao Corporation and Estee Lauder; consulting fees from Pola Chemical Corporation; and honoraria for lectures from Maruho, Sato Pharmaceutical, Eli Lilly Japan, UCB Japan, AbbVie, Taiho Pharmaceutical, Sun Pharmaceutical Industries Limited, Novartis, Eisai, Boehringer Ingelheim Japan, Bristol Myers, Grafa Laboratories Corporation, and Sanofi. Naoko Matsubara, Masahiko Nakayama, and Eri Iwashita are employees of AbbVie GK. Keiichi Yamanaka received research grants from Eli Lilly Japan, Leo Pharma, Maruho, Sasaki Chemical, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Torii Pharmaceutical, KAKENHI, Nihon Kayaku, Kaken Pharmaceutical, Nihon Seiyaku, Boehringer Ingelheim, and Otsuka Pharmaceutical and lecture fees from AbbVie, Otsuka Pharmaceutical, Astellas Seiyaku, Boehringer Ingelheim, Pfizer, Celgene, UCB Japan, Daiichi-Sankyo, Bristol Myers, Eisai, Kaken Pharmaceutical, Eli Lilly Japan, Nobel Pharma, Janssen, Kyowa Kirin, Leo Pharma, Maruho, Mitsubishi Tanabe, Nippon Kayaku, Nippon Zouki, Novartis, Sato Seiyaku, Sanofi, Sun Pharmaceutical Industries, Taiho Pharmaceutical, and Torii Pharmaceutical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was reviewed and authorized by the Pharmaceuticals and Medical Devices Agency. Although not strictly required by the GPSP, ethical approval from institutional review boards or ethics committees of the participating medical centers was obtained when required. Patients or their legal guardians provided informed consent to participate in the study prior to initiating adalimumab treatment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}